Response to comment by P. Vassilakopoulos and colleagues

Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025

C to U RNA editing of MFN1 is regulated by ADARB1 and associates with favourable prognosis in chronic lymphocytic leukemia.

Scientific reports·2025

Sustained survival benefit of emicizumab and postponed immunosuppression in acquired hemophilia A.

Blood advances·2025

Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025

Patient-reported Outcomes in KEYLYNK-010: Pembrolizumab Plus Olaparib Versus Abiraterone or Enzalutamide for Participants with Biomarker-unselected, Previously Treated Metastatic Castration-resistant Prostate Cancer.

European urology oncology·2025

Fertility in patients with advanced-stage classic Hodgkin lymphoma treated with BrECADD versus eBEACOPP: a secondary analysis of the multicentre, randomised, parallel, open-label, phase 3 HD21 trial.

The Lancet. Oncology·2025

Genetic thrombophilia in cancer-associated thrombosis: the fly plowing with the ox or an old player's new role?

Haematologica·2026

From prognostic discrimination to clinical utility in high-risk myeloma. Comment on: "Risk factors and their contributions to prognosis in multiple myeloma".

Haematologica·2026

Learning from relapse: how MajesTEC-1 immune profiling points the way to next-generation bispecific strategies.

Haematologica·2026

Making remissions last: the promise of maintenance in primary central nervous system lymphoma.

Haematologica·2026

Venetoclax combined with high-dose cytarabine and mitoxantrone for relapsed or refractory acute myeloid leukemia: outcomes and risk stratification.

Haematologica·2026

The many faces (and phenotypes) of BCR::ABL1-driven acute leukemia.

Haematologica·2026

Anakinra Prophylaxis for Recurrent Severe ICANS Associated With Tarlatamab in Small Cell Lung Cancer: Case Report.

JTO clinical and research reports·2026

Prognostic value of CD103+ tumor-infiltrating lymphocytes in bladder cancer: A systematic review and meta-analysis.

Urologic oncology·2026

Immunotherapy for Glioma: A compartmental framework for resistance and rational combination design.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026

B-cells in breast cancer: current insights and challenges.

Frontiers in oncology·2026

Tumor immunosenescence drives breast cancer progression and therapeutic resistance: mechanisms and emerging interventions.

Frontiers in oncology·2026

The heterogeneous and dynamic immune-tumor interface in breast cancer.

Frontiers in oncology·2026

Related Experiment Videos

Response to comment by P. Vassilakopoulos and colleagues

Related Concept Videos

Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma.

C to U RNA editing of MFN1 is regulated by ADARB1 and associates with favourable prognosis in chronic lymphocytic leukemia.

Sustained survival benefit of emicizumab and postponed immunosuppression in acquired hemophilia A.

Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study.

Patient-reported Outcomes in KEYLYNK-010: Pembrolizumab Plus Olaparib Versus Abiraterone or Enzalutamide for Participants with Biomarker-unselected, Previously Treated Metastatic Castration-resistant Prostate Cancer.

Fertility in patients with advanced-stage classic Hodgkin lymphoma treated with BrECADD versus eBEACOPP: a secondary analysis of the multicentre, randomised, parallel, open-label, phase 3 HD21 trial.

Genetic thrombophilia in cancer-associated thrombosis: the fly plowing with the ox or an old player's new role?

From prognostic discrimination to clinical utility in high-risk myeloma. Comment on: "Risk factors and their contributions to prognosis in multiple myeloma".

Learning from relapse: how MajesTEC-1 immune profiling points the way to next-generation bispecific strategies.

Making remissions last: the promise of maintenance in primary central nervous system lymphoma.

Venetoclax combined with high-dose cytarabine and mitoxantrone for relapsed or refractory acute myeloid leukemia: outcomes and risk stratification.

The many faces (and phenotypes) of BCR::ABL1-driven acute leukemia.

Anakinra Prophylaxis for Recurrent Severe ICANS Associated With Tarlatamab in Small Cell Lung Cancer: Case Report.

Prognostic value of CD103+ tumor-infiltrating lymphocytes in bladder cancer: A systematic review and meta-analysis.

Immunotherapy for Glioma: A compartmental framework for resistance and rational combination design.

B-cells in breast cancer: current insights and challenges.

Tumor immunosenescence drives breast cancer progression and therapeutic resistance: mechanisms and emerging interventions.

The heterogeneous and dynamic immune-tumor interface in breast cancer.

Related Experiment Videos

Response to comment by P. Vassilakopoulos and colleagues

Related Concept Videos

Related Articles